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Summary
Objectives: The conventional in vitro models simulate pharmacodynamics of antibi-
otics in the treatment of planktonic Pseudomonas aeruginosa. In this study, we
propose a novel pharmacodynamic model of oﬂoxacin activity in the treatment of
P. aeruginosa bioﬁlm.
Methods: P. aeruginosa bioﬁlm carrying coupons were suspended in a continuous
ﬂow central compartment bioreactor (CCB). In the CCB, the pharmacokinetics of
different oﬂoxacin dosing regimens were simulated. Samples from the coupons and
the CCB were assessed for viability of the bioﬁlm and the shedding planktonic cells,
respectively, over 24 h. In addition, oﬂoxacin concentrations were assessed in each
sample withdrawn for the CCB using bioassay method.
Results: The microbiological outcomes on P. aeruginosa bioﬁlm and the shedding
planktonic cells in response to different oﬂoxacin dosing regimens were not parallel
and this may explain the non-coincidence of microbiological and clinical outcomes
with bioﬁlm associated infections.
Conclusion: The current study has introduced unprecedented novel dynamic model
for the assessment of the microbiological outcome on both bioﬁlm and shedding
planktonic cells of P. aeruginosa in response to different dosing regimens of oﬂoxacin
which in turn can simulate the clinical outcomes in bioﬁlm associated infections of P.
aeruginosa, e.g. cystic ﬁbrosis. Furthermore, different scenarios of antibiotic dosing
regimens against bioﬁlm related infections can be mimicked using such model.
Published by Elsevier Ltd.
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uovel in vitro pharmacodynamic model
ntroduction
he bacterial bioﬁlms are structured communities
f bacterial cells enclosed in a self-produced extra-
ellular polymeric matrices and can develop on
nert surfaces or living tissues [1]. Bioﬁlm is a
hielding pattern of growth for bacteria, enabling
he organism to withstand harsh environmental
onditions, and bioﬁlm embedded bacteria can
urvive the use of antibiotics and antiseptics at con-
entrations hundreds or even thousands of times
igher than the concentrations that kill planktonic
ells of the same species [2,3]. The progress of
mature Pseudomonas aeruginosa bioﬁlm from
lanktonic cells passes through initial adherence
f microcolonies on a surface and maturation of
ttached bacteria into a differentiated bioﬁlm.
fter bioﬁlm maturation, planktonic colonies of
acteria shed from the bioﬁlm to colonize new sur-
aces or tissues. In case of cystic ﬁbrosis patients,
ucoid strains of P. aeruginosa colonize the lung
eading to recurrent infectious pulmonary exacer-
ations, decreased lung function and eventually
eath [4].
Pharmacodynamic in vitro models have been
roved to be efﬁcient and powerful tools for
ptimizing antimicrobial dosing to prevent the
mergence of resistance and they can accurately
redict alterations in susceptible and resistant
acterial subpopulations over time as a func-
ion of antimicrobial concentration. Such models
ould potentially be used to narrow the range of
nimal and clinical trials required for drug devel-
pment and approval as well as for optimizing
he dosing regimens to prevent the emergence of
esistance [5]. Different in vitro models applying
harmacokinetic parameters of ﬂuoroquinolones
gainst planktonic forms of P. aeruginosa were con-
ucted to estimate their clinical outcomes [6—8].
owever, P. aeruginosa strains develop antibiotic-
esistant bioﬁlms in different chronic infections
nd eradication of such bioﬁlms is hard to be
chieved due to the development of protective
xtracellular polymeric matrix as well as the
ntrinsic mechanisms of resistance developed by
ioﬁlm ensconced persisting bacteria [9—15] and
n such cases the conventional in vitro models
ay not be proper for prediction of the clin-
cal outcomes. In this study, we established a
ovel in vitro pharmacodynamic bioreactor to
ssess the microbiological outcomes of different
ﬂoxacin dosing regimens, as a model for ﬂuo-
oquinolone therapy, on P. aeruginosa bioﬁlm as
ell as the shedding planktonic cells from that
ioﬁlm.
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aterials and methods
icroorganisms and supplements
. aeruginosa ATCC 27853 and Escherichia coli
TCC 25922 were obtained from the American
ype Culture Collection (Manassas, VA, USA) and
ere stored in cryotubes (Thermo Fisher Scien-
iﬁc, Inc., Waltham, MA, USA) at −80 ◦C. Cultures
ere prepared according to ATCC guidelines. All
ell culture media and supplements were pur-
hased from Sigma—Aldrich (St. Louis, MO). All
ﬂoxacin stock solutions and dilutions were pre-
ared according to the Clinical and Laboratory
tandards Institute (CLSI) guidelines M7-A7 and
100-16. Before each experiment, P. aeruginosa
TCC 27853 was subcultured onto Mueller Hinton
I (MHII) agar plates for 24 h at 37 ◦C. An inocu-
um of 1—2× 106 colony-forming units (CFU)/mL
as used in every experiment. The inoculum
as prepared using an overnight culture grown
n cation adjusted MHII broth, diluted based
n 0.5 McFarland standard (Lenexa, KS, USA)
hich is equivalent to 1.5× 108 CFU/mL and sub-
equently veriﬁed by viable cell count on MHII agar
lates.
ioﬁlm establishment on coupons
ioﬁlm of P. aeruginosa was developed on two
ets (8 Coupons/Set) of silicone coupons (Catalogue
o. 97041 from LabPure Saint-Gobain Corporation,
alley Forge, PA) using overnight MHII broth cul-
ure (50mL) of 106 CFU/mL P. aeruginosa ATCC
7853 grown under aerobic conditions at 37 ◦C
or 18 h without shaking [16]. Establishment of P.
eruginosa bioﬁlm on silicone coupons was con-
rmed by using scanning electron microscopy. The
hoto was captured using variable pressure JEOL
canning electron microscope (Model JSM-6490LV,
eabody, Massachusetts) equipped with a tungsten
lament with accelerating voltages of 15—20 kV
nd chamber pressure from 60 to 70 Pa accord-
ng to the method described by Heerden et al.
17].
entral compartment bioreactor setup
he central compartment bioreactor (CCB) was
sed to assess the effect of different oﬂoxacin
osing regimens on P. aeruginosa bioﬁlm and the
hedding planktonic cells from that bioﬁlm. The
CB is a conical glass vessel of total volume of
00mL. The CCB provides 550mL of operational
uid capacity and covered with an autoclavable
122
Figure 1 Schematic diagram for the central com-
partment bioreactor (CCB) containing Pseudomonas
aeruginosa bioﬁlm coated coupons and simulating the
pharmacokinetics of oﬂoxacin dosing regimens. Antibi-
otic was administered to the CCB by bolus injections and
the volume of the medium within the CCB was kept con-
stant by setting the Masterﬂex pumps from the dilution
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creservoir and to the waste reservoir at the same rates,
yielding an exponential decline of oﬂoxacin concentra-
tions.
cap containing ﬁve ports (an inlet of fresh medium,
an efﬂuent connected to a waste vessel, coupons-
suspending port, antibiotic injection port, and
sampling port). For each experiment, two CCB
were used, one for testing the oﬂoxacin dosing
regimen and the other for the control, and each
bioreactor was connected through silicone tubing
to polypropylene reservoir containing 4 L of the
medium (Fig. 1). The rate of the fresh medium
inlet and exhaust outlet were controlled using two
Masterﬂex peristaltic pumps (Cole Parmer, Vernon
Hills, IL, USA). The rates of the Masterﬂex pumps
were adjusted to yield a mono-exponential kinetic
process, simulating the oﬂoxacin pharmacokinetics
in each dosing regimen, according to the following
equation [18]:
Q =
(
0.693
T1/2
)
× Vc
where Q is the pump rate, Vc is the operational
volume of the CCB, and T1/2 is the simulated elim-
ination half-life.
The two central compartment bioreactors were
contained in water bath at temperature 37 ◦C and
placed upon a digitally controlled magnetic stirring
plate (Thermo Fisher Scientiﬁc, Inc., Waltham, MA)
adjusted at 100 RPM to assure constant drug dis-
tribution in the CCB and consistent shear to the
bioﬁlm coated coupons. It has been reported that
bioﬁlms can adjust the mechanical properties of
their slime in response to hydrodynamic shear and
high-shear conditions stimulate the bioﬁlm embed-
ded cells to produce stronger slime matrix and
subsequently more robustly adherent cells than do
e
1
i
(
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ioﬁlms formed on living tissues [19—21], therefore
he agitation in the CCB was maintained at low rate
uring the whole experiments. The temperature
as maintained constant at 37 ◦C, for simulation
f human body temperature, through implementing
thermo-sensitive feedback probe (Thermo Fisher
cientiﬁc, Inc., Waltham, MA) in the water bath
hroughout the experiments.
In each experiment, two coupons (coupon
imensions: 7mm in diameter and 10mm thick)
epresenting the treated and the control bioﬁlms
ere excised from the bioreactors at speciﬁed time
ntervals (0, 1, 2, 6, 12, 19, and 24 h) and each
oupon was placed in Eppendorf tube containing
50L normal saline. The Eppendorf tubes were
hen sonicated for 5min in ultrasonic water bath
Fisher Scientiﬁc, Model FS-60, frequency of 40 kHz,
ltrasonic power of 130W) followed by vigorous vor-
exing for 60 s to dislodge and disperse the cells
rom the bioﬁlm. Since detachment process and
hedding of planktonic cells from bioﬁlms are also
ubstantial factors to be considered, as they play
undamental roles in dissemination, contamination,
nd ultimately long-term survival of bacteria [22],
amples (1mL) were withdrawn directly from the
CB at each time point. The samples withdrawn
irectly from the CCB (shedding planktonic cells)
s well as the sonicated coupon samples (bioﬁlm-
mbedded cells) were serially diluted ten-fold to
e counted on MHII agar plates [23]. After incu-
ation at 37 ◦C for 24 h, the viable cell counts
ere determined and used in the calculation of
og10 CFU/mL and log10 CFU/Coupon for shedding
lanktonic cells in CCB and bioﬁlm-embedded cells
n coupons, respectively. The viable count experi-
ents were repeated in triplicates and the averages
f the viable cell counts were graphically rep-
esented for different oﬂoxacin dosing regimens.
y applying ANOVA for statistical analyses, the
esults were considered signiﬁcant at P < 0.05.
egarding the effect of different oﬂoxacin dos-
ng regimens on bioﬁlm-embedded and shedding
ells, Pearson correlation test was applied for cal-
ulation of correlation coefﬁcient (R2) using Prism
oftware (GraphPad Software Inc., La Jolla, CA,
SA).
The pharmacokinetic characteristics for
ﬂoxacin in vivo were simulated in our in vitro
harmacodynamic model at a peak plasma
oncentration (CPmax) of 2.5mg/L (every 12 h
orresponding to 200mg twice daily) and its
limination T1/2 of 4.5 h, CPmax of 5mg/L (every
2 h corresponding to 400mg twice daily) and
ts elimination T1/2 of 4.5 h, and CPmax of 8mg/L
every 24 h corresponding to 650mg once daily) and
ts elimination T1/2 of 6 h and all the experiments
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where C is the concentration at time t, C0 is
the initial concentration at time 0, and K is the
ﬁrst order elimination rate constant which equals
to 0.693/T1/2. The average values of the mea-
sured oﬂoxacin concentrations at various sample
points for all experiments were correlated with the
calculated values for validation of the simulated
pharmacokinetic proﬁles of oﬂoxacin different dos-
ing regimens and the pooled data were represented
graphically.
Results
Establishment of P. aeruginosa bioﬁlm on the
coupons was conﬁrmed by using scanning elec-
tron microscopy and Fig. 2 shows P. aeruginosa
encased within the extracellular polysaccharide
matrix of the bioﬁlm on the surface of the silicone
coupon. For oﬂoxacin dosing regimen 200mg BID
which was simulated by CPmax of 2.5mg/L every
12 h and elimination T1/2 of 4.5 h, the ﬁrst dose
decreased the bioburden by up to 6 log10 and 8 log10
for bioﬁlm and planktonic shedding cells, respec-
tively as compared to that of their controls. While,
the second dose (CPmax of 2.5mg/L) could nei-
ther inhibit bioﬁlm nor planktonic cells (Fig. 3).
On the other hand, the ﬁrst dose of oﬂoxacin
400mg BID, which was represented by CPmax of
5mg/L every 12 h and elimination T1/2 of 4.5 h,
showed bioburden reduction by up to 6 log10 and
10 log10 for bioﬁlm and planktonic shedding cells,
respectively as compared to that of the control.
Unlike to the dose regimen of 200mg oﬂoxacin
BID, the planktonic shedding cells could not be
detected at 6 h sample point. However, similar toovel in vitro pharmacodynamic model
ere conducted over 24 h for different dosing
egimens and growth controls [6].
alidation of the pharmacodynamic system
alibration curve for oﬂoxacin
ﬂoxacin calibration curve was constructed using
he bioassay with Escherichia coli ATCC 25922
ccording to the method described by Joos et
l. [24] with some modiﬁcations [23]. Brieﬂy,
vernight broth culture of Escherichia coli ATCC
5922 was diluted in Mueller Hinton broth to
.5× 108 CFU/mL (0.5 McFarland standard) and
sed to inoculate molten MHII agar to give ﬁnal
ount of 1—2× 107 CFU/mL within the seed agar
lates. After solidiﬁcation of agar plates, wells of
mm diameter were made and ﬁlled with 50L of
he standard oﬂoxacin solutions within the concen-
ration range from 0.125 to 32.0g/mL. The plates
ere then incubated for 20 h at 37 ◦C. After incu-
ation, the inhibition zone diameters (IZDs) were
easured in millimeter (mm) and the averages of
ZD triplicates plotted against log10 concentration
g/mL) for obtaining the best-ﬁt line of the cali-
ration curve.
ssessment of oﬂoxacin concentrations
ﬂoxacin concentrations in the central compart-
ent bioreactor (CCB) were assessed at each
ample point with different dosing regimens. For
ﬂoxacin bioassay, 500L of each sample with-
rawn from the CCBwere centrifuged at 12,500 RPM
Minispin: Eppendorf North America, Westbury, NY)
or 10min at 4 ◦C and the supernatants were care-
ully aspirated for the assessment of oﬂoxacin
oncentrations using the same protocol previously
escribed under calibration curve for oﬂoxacin.
fter incubation of the assay plates, the IZDs were
easured and the averages of IZD triplicates were
pplied for calculation of oﬂoxacin concentration
t each sample point.
orrelation between measured and
alculated oﬂoxacin concentrations
oncentrations of oﬂoxacin in the central com-
artment bioreactor were calculated depending on
Pmax and elimination T1/2 at each sample point for
ifferent dosing regimens according to the follow-
ng equation [25]:
= C0e−kt
Figure 2 Scanning electron micrograph illustrating the
appearance of P. aeruginosa bioﬁlm on the silicone
coupon.
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Figure 3 Effect of oﬂoxacin 200mg BID against bioﬁlm
and shedding planktonic cells of P. aeruginosa ATCC 27853
simulated with CPmax 2.5mg/L every 12 h and its elimina-
tion T1/2 of 4.5 h. Data expressed as mean values± SD
of viable cell counts, where CFU/mL for shedding plank-
tonic cells, CFU/Coupon for bioﬁlm embedded cells on
coupons, CB; control bioﬁlm, CS; control shedding, TB
Figure 5 Effect of oﬂoxacin 650mg once daily against
bioﬁlm and shedding planktonic cells of P. aeruginosa
ATCC 27853 simulated with CPmax 8mg/L every 24 h and
its elimination half-life T1/2 of 6 h. Data expressed as
mean values± SD of viable cell counts, where CFU/mL
for shedding planktonic cells, CFU/Coupon for bioﬁlm
embedded cells on coupons, CB; control bioﬁlm, CS;
control shedding, TB (8.0g/mL); test bioﬁlm, TS
(
c
s
d
u
T
n(2.5g/mL); test bioﬁlm, TS (2.5g/mL); test shedding
planktonic cells. Arrows indicate the dosing time.
the dose regimen of 200mg oﬂoxacin BID, the sec-
ond dose (CPmax of 5mg/L) could neither inhibit
bioﬁlm nor planktonic shedding cells which may
indicate development of resistant subpopulations
(Fig. 4). The results showed that there was no pro-
nounced difference in the rate and magnitude of
the bioﬁlm killing between 200mg BID and 400mg
BID oﬂoxacin dosing regimens, however such dif-
ference was more prominent in case of planktonic
Figure 4 Effect of oﬂoxacin 400mg BID against bioﬁlm
and shedding planktonic cells of P. aeruginosa ATCC 27853
simulated with CPmax 5mg/L every 12 h and its elimina-
tion T1/2 of 4.5 h. Data expressed as mean values± SD
of viable cell counts, where CFU/mL for shedding plank-
tonic cells, CFU/Coupon for bioﬁlm embedded cells on
coupons, CB; control bioﬁlm, CS; control shedding, TB
(5.0g/mL); test bioﬁlm, TS (5.0g/mL); test shedding
planktonic cells. Arrows indicate the dosing time.
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(8.0g/mL); test shedding planktonic cells. Arrow indi-
ates the dosing time.
hedding cells (Figs. 3 and 4). Regarding oﬂoxacin
osing regimen 650mg once daily, which was sim-
lated by CPmax of 8mg/L and longer elimination
1/2 of 6 h, such dose could decrease P. aerugi-
osa ATCC 27853 bioburden by up to 7 log10 and
0 log10 for bioﬁlm and shedding cells, respectively
s compared to that of the control. Furthermore,
hedding planktonic cells could not be detected
n the central compartment bioreactor from 2 to
0 h with such dosing regimen (Fig. 5). Concerning
he effect of different oﬂoxacin dosing regimens on
ioﬁlm-embedded and shedding cells, Pearson cor-
elation test revealed weak correlation (R2 = 0.682)
etween antimicrobial outcomes of oﬂoxacin on
oth forms of growth.
In this study, standard calibration curve of
ﬂoxacin was established using bioassay for
ssessment of oﬂoxacin concentrations at differ-
nt sample points withdrawn from the central
ompartment bioreactor. The calibration curve
f oﬂoxacin using bioassay technique against
scherichia coli ATCC 25922 demonstrated good lin-
arity (R2 = 0.9889) over a concentration range of
.125—32.0g/mL (Fig. 6).
For validation of the pharmacodynamic model,
he microbiologically measured oﬂoxacin con-
entrations were correlated with the calcu-
ated values at different sample points and the
esults veriﬁed satisfactory correlation coefﬁcient
R2 = 0.9441) depending on CPmax and elimina-
ion half-lives T1/2 of different dosing regimens
Fig. 7).
Novel in vitro pharmacodynamic model
F
A
r
D
O
t
u
i
h
m
r
s
r
a
b
t
g
c
o
e
i
t
a
F
c
p
i
h
t
i
[
p
k
[
m
o
p
c
t
h
t
f
n
m
P
r
q
o
c
s
e
r
c
o
t
d
o
pigure 6 Bioassay of oﬂoxacin using Escherichia coli
TCC 25922 as standard strain within the concentration
ange of 0.125—32.0g/mL.
iscussion
rganization of microorganisms as bioﬁlms is
hought to confer numerous survival mechanisms
pon the individually living organisms and these
nclude not only protection from the in vivo
ost immune defense, but also provision and
aintenance of appropriate physico-chemical envi-
onments for such organisms [2]. Regardless of their
ite of occurrence, bacterial bioﬁlms exhibit a noto-
ious reluctance towards different antimicrobial
gents [26]. In this light, treatment of bacterial
ioﬁlms with antibiotics, at concentrations proven
o be effective against their planktonic cultures,
enerally fails to possess any signiﬁcant clinical out-
omes [27].
The globally rapid increase in the prevalence
f antibiotic-resistant microorganisms has threat-
ned the ability of physicians to treat serious
nfections and several studies have demonstrated
hat infections caused by antibiotic-resistant P.
eruginosa are more difﬁcult to treat, result-
igure 7 Correlation between the measured oﬂoxacin
oncentrations and the calculated ones at various sample
oints of the tested dosing regimens.
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ng in excess morbidity and mortality as well as
igher health care costs. Therefore, modeling of
he dosing regimens is imperative for suppress-
ng the emergence of antibiotic-resistant mutants
28].
Mimicking of human pharmacokinetics in vitro
rovides valuable information with respect to
inetics of killing of different microorganisms
29]. However, the frequently employed in vitro
odels estimate the clinical outcomes of antibi-
tic therapy depending on the implication of
lanktonic forms of growth [6,7,30—33], shedding
ells from the bioﬁlm as a surrogate marker of
he bioﬁlm embedded-cells viability [27,34,35] or
omogenization of simulated endocardial vegeta-
ions [36—38].
In this study, we developed a novel bioreactor
or simulating the actual in vivo pharmacoki-
etic parameters in an in vitro pharmacodynamic
odel on both bioﬁlm and shedding cells of
. aeruginosa in response to different dosing
egimens of oﬂoxacin as an example of ﬂuoro-
uinolone therapy. Since pharmacokinetic proﬁle
f oﬂoxacin is more favorable than that of
iproﬂoxacin [39], oﬂoxacin was selected in this
tudy.
By increasing the dose, oﬂoxacin generally
xhibited a faster rate and larger extent of bacte-
ial kill against both bioﬁlm and shedding planktonic
ells of P. aeruginosa. Nevertheless, themagnitudes
f planktonic cells killing were signiﬁcantly higher
han that of bioﬁlm at different applied oﬂoxacin
osing regimens and this may be attributed to one
r more of the various mechanisms that have been
roposed to explain the recalcitrance of bacte-
ial bioﬁlms towards antimicrobial agents including
he role of the glycocalyx [40,41] and extracellu-
ar enzymes [42—45] in restricting the access of the
ntimicrobial agents or development of resistance
ubpopulations within the bioﬁlms [27]. Regarding
he magnitude of oﬂoxacin killing on planktonic
hedding cells, the most favorable pharmacoki-
etic dosing regimen was obtained with CPmax
f 8mg/L and elimination T1/2 of 6 h and these
ata are consistent with that described previously
6]. However, none of the applied oﬂoxacin dosing
egimens could eradicate the bioﬁlm of P. aerug-
nosa ATCC 27853 revealing unparallel response
etween bioﬁlm and shedding planktonic cells to
he antimicrobial effect of oﬂoxacin dosing reg-
mens. It is worth mentioning that the second
oses of oﬂoxacin, with dosing regimens of 200mg
ID and 400mg BID, had no inhibitory effect on
ioﬁlm or shedding cells and these colonies showed
levated MIC values (4—16×) against different ﬂu-
roquinolones as compared to that of the parent
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strain (data not shown). These results are in concor-
dance with the hypothesis that the drug-susceptible
population may be completely replaced with resis-
tant mutants over time. Accordingly, this may be
manifested clinically as failure of the infection to
respond to the therapy or a relapse of infection
with drug-resistant mutants shortly after a pre-
scribed course of antibiotic therapy is completed
[28].
The bacterial bioburden in a lung infection
often exceeds 1010 [46,47] and this was well sim-
ulated through P. aeruginosa ATCC 27853 bioﬁlm
burden, approximately 1012 CFU/coupon, in the
central compartment bioreactor. Jumbe et al.
found that microbiological outcome of levoﬂoxacin,
a ﬂuoroquinolone, treatment of P. aeruginosa
ATCC 27853 infections was inoculum dependent
in their model and selection of drug resistant
P. aeruginosa mutants from planktonic culture
in vitro was common and occurred with a fre-
quency of 0.1—2× 10−6. The same authors reported
that at the higher infection inoculum, the micro-
bial population burden signiﬁcantly exceeded the
mutation frequency and the resistant population
was able to survive and subsequently a sub-
population of mutant organisms that behaved
quite differently under antibiotic selective pres-
sure could preferentially emerge and predominate
[28].
Some models revealed that resistance ampliﬁca-
tion can be prevented with appropriate antibiotic
dosing regimens. However, these models employed
planktonic cultures of P. aeruginosa [28]. There-
fore, they provide little guidance about their
clinical relevance in cases of bioﬁlm associ-
ated infections. Since the proposed model in
this study has been validated and proved to be
adequately simulating the pharmacokinetics of dif-
ferent oﬂoxacin dosing regimens, the obtained
data might be translated into clinical practice as
treatment with oﬂoxacin does not appear to pos-
sess promising outcome in case of P. aeruginosa
bioﬁlm associated infections at its clinically achiev-
able concentrations. Furthermore, the proposed
model in this study can be utilized for the assess-
ment of the microbiological outcomes of different
antibiotics against bioﬁlm producing organisms and
that could be relevant to the clinical outcomes in
patient with bioﬁlm associated infections such as
cystic ﬁbrosis.
The principal ﬁnding from this study was the
absence of consistent microbiological outcome
between the efﬁcacy of oﬂoxacin, as an example
of ﬂuoroquinolone therapy, on bioﬁlm embedded
cells and shedding planktonic cells of P. aeruginosa
under the same pharmacokinetics of drug exposure
[A.M. Noreddin, W.F. Elkhatib
hich consequently emphasizes the signiﬁcance of
uch novel pharmacodynamic model for evaluating
he antimicrobial activities of different antibiotics
n both bioﬁlm and planktonic forms of microbial
rowths simultaneously. Furthermore, the proposed
odel can be employed in the development of new
nd rational drug-dosing regimens to prevent or
elay the emergence of resistance from bacterial
ioﬁlms as well as to prolong the utility of cur-
ently available anti-infective agents in the clinical
ettings.
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